Mediherb

Main information

Documents

Localization

  • Available in:
  • Mediherb Joint Defence
    Australia
  • Language:
  • English

Other information

Status

  • Source:
  • Dept. of Health,Therapeutic Goods Administration - Australia
  • Authorization number:
  • 221769
  • Last update:
  • 08-10-2017

Public Assessment Report

Public Summary

Summary for ARTG Entry:

221769

Mediherb Joint Defence

ARTG entry for

Medicine Listed

Sponsor

Integria Healthcare Australia Pty Ltd

Postal Address

PO Box 4854,EIGHT MILE PLAINS, QLD, 4113

Australia

ARTG Start Date

27/03/2014

Product category

Medicine

Status

Active

Approval area

Listed Medicines

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in

the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine,

(b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is

sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be

kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records

to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted

in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office

of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors

of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified

of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine

outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National

Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1. Mediherb Joint Defence

Product Type

Single Medicine Product

Effective date

27/03/2014

Warnings

Derived from seafood.

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.

This product contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not

be exceeded.

For practitioner dispensing only.

If symptoms persist consult your healthcare practitioner (or words to that effect).

Standard Indications

May help reduce joint swelling associated with arthritis.

May assist in the management of osteoarthritic pain. [Warning S required]

May assist in the management of osteoarthritis. [Warning S required]

Symptomatic relief of osteoarthritis. [Warning S required]

May help increase joint mobility associated with arthritis.

Temporary relief of the pain of rheumatoid arthritis. [Warning S required]

Temporary relief of the pain of osteoarthritis (or) Temporary relief of osteoarthritic pain. [Warning S required]

Temporary relief of the pain of arthritis. (or) Temporary relief of arthritic pain. [Warning S required]

May help reduce joint inflammation associated with arthritis.

Specific Indications

Research shows that glucosamine and chondroitin sulphate may reduce joint inflammation and swelling, joint mobility, and provide temporary relief of the

pain of osteoarthritis

Supplementation with glucosamine and chondroitin provides substrates for the production of proteoglycans, which helps maintain and protects joint

cartilage

Boswellia has been traditionally used in Ayurvedic medicine for rheumatic disorders and has an anti-inflammatory action

Antioxidant / Has anti-oxidising effect

Has been formulated to provide support for inflammatory conditions

Public Summary

Page 1 of

Produced at 26.11.2017 at 12:35:49 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit www.tga.gov.au for contact information

Helps reduce inflammation

Glucosamine acts as a building block for cartilage formation and repair

Helps in maintaining joint health / Supports healthy joint function

Helps to protect against the deterioration of cartilage

Helps in the development and maintenance of cartilage

Supports the growth of healthy joint cartilage

Helps in maintaining healthy cartilage

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1. Formulation 1

Dosage Form

Tablet, film coated

Route of Administration

Oral

Visual Identification

Active Ingredients

Ascorbic acid

50 mg

Borax

8.38 mg

Boswellia serrata

139 mg

Equivalent: Boswellia serrata (Dry)

973 mg

bovine chondroitin sulfate

300 mg

Copper gluconate

3.57 mg

Glucosamine hydrochloride

500 mg

Manganese amino acid chelate

50 mg

Selenomethionine

20 microgram

Zinc gluconate

50 mg

© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior

written approval from the Commonwealth.Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

Public Summary

Page 2 of

Produced at 26.11.2017 at 12:35:49 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit www.tga.gov.au for contact information